Summit Therapeutics discloses going concern doubt alongside $380 million stock offering

Summit Therapeutics Inc. filed a prospectus supplement on July 23, 2026 for a new at-the-market equity program that would let it sell up to $380,000,000 in common stock through J.P. Morgan Securities LLC as sales agent, under a distribution agreement dated July 23, 2026¹. The stock closed at $14.74 per share on The Nasdaq Global Market on July 22, 2026.¹ J.P. Morgan will be paid up to a 3.0% commission on the gross sales price of any stock sold under the arrangement.¹

Summit said it plans to use the proceeds, together with existing cash, cash equivalents and short-term investments, to continue developing ivonescimab, including trials in non-small cell lung cancer, colorectal cancer and other solid tumors, with the remainder going to working capital and general corporate purposes.¹

The filing also disclosed a financial warning. Summit said it does not currently have sufficient working capital to fund planned operations for the next twelve months, and cited uncertainty about its ability to raise additional capital, creating substantial doubt about its ability to continue as a going concern.¹ That conclusion came from the company's quarterly report covering the period ended June 30, 2026, which was submitted to regulators the same day as this offering document.¹

On the clinical side, an updated HARMONi study analysis with a June 2026 data cutoff showed a consistent overall survival trend between western and Asian patients, with a hazard ratio of 0.76 observed in both the full population and the western subgroup.¹

Summit also disclosed a new partnership. In July 2026, the company entered a clinical trial collaboration with Arcus Biosciences to test ivonescimab alongside Arcus's HIF-2-alpha inhibitor casdatifan in patients with clear cell renal cell carcinoma.¹ Both companies will share the study's costs and each will supply drug for the trial, with no additional milestone payments or royalty terms attached.¹